Results 261 to 270 of about 257,826 (338)

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

open access: yesBritish Journal of Haematology, EarlyView.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux   +21 more
wiley   +1 more source

Distinct characteristics and social determinants in adult T‐cell leukaemia/lymphoma patients at a tertiary cancer centre in Canada

open access: yesBritish Journal of Haematology, EarlyView.
Adult T‐cell leukaemia/lymphoma (ATLL) is a rare, aggressive cancer linked to HTLV‐1, with poor outcomes. We analysed 79 ATLL patients (1993–2023) at our institution. The median age at diagnosis was 47 years, with 72% of patients of Caribbean origin. Median progression‐free and overall survival were 10.2 and 16.2 months respectively. CNS involvement at
Tomohiro Aoki   +11 more
wiley   +1 more source

The role of blinatumomab in adult acute B lymphoblastic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Blinatumomab, a CD19‐directed bispecific T‐cell engager, has become a crucial part of BCP‐ALL therapy in r/r disease, MRD‐positive disease and has recently been implemented into first‐line therapy of BCP‐ALL. This review discusses important clinical trials with a focus on blinatumomab in first‐line therapy of adult BCP‐ALL.
Anne C. Wilke, Nicola Gökbuget
wiley   +1 more source

Combination of fixed low‐dose nivolumab and bendamustine in children with high‐risk relapsed/refractory classical Hodgkin lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
A retrospective study of 18 pediatric patients with high‐risk relapsed/refractory classical Hodgkin lymphoma demonstrated that a fixed low‐dose combination of nivolumab and bendamustine achieved an 88% complete response rate, with 1‐year progression‐free survival (PFS) of 88.2% and overall survival (OS) of 94.4%.
Shyam Srinivasan   +12 more
wiley   +1 more source

Anaplastic large cell lymphoma in children and adolescents

open access: yesBritish Journal of Haematology, EarlyView.
Summary Anaplastic lymphoma kinase (ALK)‐positive anaplastic large‐cell lymphoma (ALCL) accounts for >95% of ALCL cases in children and adolescents. The first description of ALCL as a CD30‐positive lymphoma in 1985 was followed by the detection of chromosomal translocations involving the ALK gene at chromosome 2p23.
Eric J. Lowe, Wilhelm Woessmann
wiley   +1 more source

Home - About - Disclaimer - Privacy